Literature DB >> 7307229

Pharmacokinetics of vincristine sulfate in children.

V S Sethi, J C Kimball.   

Abstract

A radioimmunoassay was used to measure vincristine sulfate concentrations in the serum of four children with malignancies (ages 5-16 years) following intravenous (IV) bolus injections. The pharmacokinetic data were analyzed by a non-linear least-square regression program NONLIN. A three-compartment open model fitted the raw data better than a two-compartment model in three patients. In the other patient the raw data fitted a two-compartment open model. The half-lives of the triphasic decay curves alpha, beta, and gamma were 2.6, 41, and 1,531 min (25.5 h), respectively. The mean apparent volume of the central compartment was 3.25 l, and the the volume of distribution per 1.73 m2 body surface area at steady state was 215.9 l. In a three-compartment open model, the first-order distribution and elimination rate constants (min-1) of vincristine were as follows: k12, 0.088; k13, 0.121; k21, 0.028; k31, 0.0026; k10, 0.045. The plasma clearance was 146.2 ml/min per 1.73 m2, while the AUC0 infinity was 27,816 nM . min. Urinary excretion in one patient demonstrated a drug concentration of greater than 1.0 X 10(-7) M in the urine up to 78 h after the injection. Up to 37% of the administered drug was excreted in the urine as vincristine and/or its metabolites by 90 h. The low elimination rate constant from poorly perfused tissues to blood plasma (k31), a large apparent volume of distribution, and a long biological half-life (25.5 h) indicate avid tissue binding from which a slow release of the drug from the body tissues occurs.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 7307229     DOI: 10.1007/bf00262326

Source DB:  PubMed          Journal:  Cancer Chemother Pharmacol        ISSN: 0344-5704            Impact factor:   3.333


  16 in total

1.  Linear pharmacokinetic equations allowing direct calculation of many needed pharmacokinetic parameters from the coefficients and exponents of polyexponential equations which have been fitted to the data.

Authors:  J G Wagner
Journal:  J Pharmacokinet Biopharm       Date:  1976-10

2.  The pharmacokinetics of [3H]-vincristine in man.

Authors:  R A Bender; M C Castle; D A Margileth; V T Oliverio
Journal:  Clin Pharmacol Ther       Date:  1977-10       Impact factor: 6.875

3.  A simple estimate of glomerular filtration rate in children derived from body length and plasma creatinine.

Authors:  G J Schwartz; G B Haycock; C M Edelmann; A Spitzer
Journal:  Pediatrics       Date:  1976-08       Impact factor: 7.124

Review 4.  Vincristine neurotoxicity.

Authors:  S Rosenthal; S Kaufman
Journal:  Ann Intern Med       Date:  1974-06       Impact factor: 25.391

5.  Estimation of human body surface area from height and weight.

Authors:  E A Gehan; S L George
Journal:  Cancer Chemother Rep       Date:  1970-08

6.  Vincristine (NSC-67574) symposium--summary and prospectives.

Authors:  J G Armstron
Journal:  Cancer Chemother Rep       Date:  1968-06

7.  Application of Akaike's information criterion (AIC) in the evaluation of linear pharmacokinetic equations.

Authors:  K Yamaoka; T Nakagawa; T Uno
Journal:  J Pharmacokinet Biopharm       Date:  1978-04

8.  A sensitive radioimmunoassay for vincristine and vinblastine.

Authors:  V S Sethi; S S Burton; D V Jackson
Journal:  Cancer Chemother Pharmacol       Date:  1980       Impact factor: 3.333

9.  Biliary excretion of vincristine.

Authors:  D V Jackson; M C Castle; R A Bender
Journal:  Clin Pharmacol Ther       Date:  1978-07       Impact factor: 6.875

10.  Pharmacokinetics of vincristine sulfate in adult cancer patients.

Authors:  V S Sethi; D V Jackson; D R White; F Richards; J J Stuart; H B Muss; M R Cooper; C L Spurr
Journal:  Cancer Res       Date:  1981-09       Impact factor: 12.701

View more
  6 in total

1.  Vincristine potentiates cytochalasin B-induced DNA fragmentation in vitro.

Authors:  M A Kolber; P Hill
Journal:  Cancer Chemother Pharmacol       Date:  1992       Impact factor: 3.333

Review 2.  Thinking outside the shunt-sterile CSF malabsorption in pilocytic astrocytomas: case series and review of the literature.

Authors:  J A Johnson; P J O'Halloran; D Crimmins; J Caird
Journal:  Childs Nerv Syst       Date:  2016-05-18       Impact factor: 1.475

Review 3.  Pharmacokinetics of anticancer drugs in children.

Authors:  W R Crom; A M Glynn-Barnhart; J H Rodman; M E Teresi; R E Kavanagh; M L Christensen; M V Relling; W E Evans
Journal:  Clin Pharmacokinet       Date:  1987-03       Impact factor: 6.447

4.  Pharmacokinetics of vincristine, vinblastine, and vindesine in rhesus monkeys.

Authors:  V S Sethi; P Surratt; C L Spurr
Journal:  Cancer Chemother Pharmacol       Date:  1984       Impact factor: 3.333

5.  An investigation of the mouse as a model for vincristine toxicity.

Authors:  S D Harrison
Journal:  Cancer Chemother Pharmacol       Date:  1983       Impact factor: 3.333

6.  Plasma and cerebrospinal fluid pharmacokinetics of vincristine and vincristine sulfate liposomes injection (VSLI, marqibo®) after intravenous administration in Non-human primates.

Authors:  Nirali N Shah; Diane E Cole; Cynthia M Lester-McCully; Alan S Wayne; Katherine E Warren; Brigitte C Widemann
Journal:  Invest New Drugs       Date:  2015-12-10       Impact factor: 3.850

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.